Greenleaf Trust Raises Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Greenleaf Trust boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,827 shares of the biopharmaceutical company's stock after buying an additional 2,279 shares during the quarter. Greenleaf Trust's holdings in Gilead Sciences were worth $3,230,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of GILD. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences during the first quarter valued at $25,000. Goodman Advisory Group LLC purchased a new stake in shares of Gilead Sciences during the first quarter valued at $29,000. Core Alternative Capital grew its holdings in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 216 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. grew its holdings in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 100 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the transaction, the chief executive officer owned 620,268 shares of the company's stock, valued at $68,489,992.56. This represents a 1.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider directly owned 121,152 shares of the company's stock, valued at $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,500 shares of company stock valued at $6,340,745. 0.27% of the stock is owned by company insiders.

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. Oppenheimer dropped their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price objective on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Morgan Stanley boosted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $111.38.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $113.24 on Thursday. The stock has a market capitalization of $140.86 billion, a price-to-earnings ratio of 23.84, a PEG ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a twelve month low of $67.65 and a twelve month high of $119.96. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The stock has a 50-day moving average of $107.40 and a 200 day moving average of $104.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. Gilead Sciences's quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($1.32) EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.79%. Gilead Sciences's payout ratio is 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.